Frequently Asked Questions

Inside the @LDH ™, the local environment is:

• strongly basic, thus protecting against the well-known acid-catalyzed degradation of potent acidic cannabinoids:
• strongly reducing, with a redox potential of 1.6 Volts (ref ACS Omega, 2021, 6, 35244-35249), thus protecting against oxidation that produces well-known "red oil" discoloration of degraded cannabinoids: and
• Additionally protective by sequestering actives in a layered solid matric. 

Our formulation technology will help companies capitalize on the popularity of botanicals including acidic cannabinoids while offering superior stability and therapeutic benefits. Furthermore, our approach leverages scientific advancements for cutting-edge, consumer-friendly products.

Stabilized acidic cannabinoids can be used for various therapeutic purposes. Both CBDA and THCA have demonstrated efficacy in conditions such as obesity, diabetes, anxiety, gastrointestinal issues such as Irritable Bowel Syndrome (IBS), nausea, neurologic conditions including seizures, dementia and inflammatory modulated pain conditions. 

The natural forms of cannabinoids in the plant—the acidic forms—have been shown to be 100 to 1,000 times more potent than their neutral cannabinoid counterparts in many in vivo studies. Microgram doses are effective against conditions such as chemo-associated nausea (ref 1: Bolognini 2013), epilepsy (ref 2: WO2017/25712), anxiety (ref 3: Pertwee 2018; Rock 2017), and depression (ref 4: Hen-Shoval 2018). Bioavailability is also 10 times higher for CBDA than for CBD (ref 5) 

So this circumvents the need to decarboxylate?

Yes, for the highly potent CBDA and other therapeutic cannabinoids. Indeed, the surge in popularity of whole-spectrum hemp oils suggests that it is CBDA, not CBD, that is responsible for the therapeutic effects of “CBD products”, a conclusion that is also supported by clinical failures of the ultrapurified, CBDA-free CBD products even at doses of 900 mg. 

References.

1) [Bolognini 2013] https://pubmed.ncbi.nlm.nih.gov/31897571/

2) [WO2017/25712]

3) [Pertwee 2018; Rock 2017] https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.14073

4) [Hen-Shoval 2023] https://pubmed.ncbi.nlm.nih.gov/36835237/

5) [Wohleb] www.linkedin.com/pulse/bioavailability-cbd-vs-cbda-rob-wohleb-phd/

Stabilized acidic cannabinoids can be used for various therapeutic purposes. Both CBDA and THCA have demonstrated efficacy in conditions such as obesity, diabetes, pain, nephropathy, Alzheimer's, and even COVID-19. The superpotency of CBDA and CBGA against anxiety is further underscored by the absence of “serotonin syndrome” effects. 

Additionally, our technology and patents apply also to cannabinoid-related compounds known as “Amorfrutins” which are free from the regulations and stigma of cannabinoids. Amorfrutins provide potent PPAR-a, PPAR-g, and Pan-PPAR activities that are therapeutic in neuroprotection, type II diabetes, and dyslipidemias, and are free from the side effects of osteoblastogenesis, hepatitis, and fluid retention seen with thiazolidinediones (TZD).

Our formulation technology and expertise allow us to make novel and combination products that offer synergistic effects, and co-formulation of two or more actives in our proprietary matrix can provide stabilization, combination/synergistic therapies, facilitated delivery, and patent protection.

Extensive research, including animal models, supports the therapeutic potential of our cannabinoid-stabilizing formulation technology. We have pending patents to support a unique and proprietary offering to those that leverage our technology.